|
| U.S. Brand
Names |
|
| Peptavlon® |

|
|
| Generic
Available |
|
|
No |

|
|
| Pharmacological Index |
|
|
Diagnostic Agent |

|
|
| Use |
|
|
Evaluate gastric acid secretory function in pernicious anemia, gastric
carcinoma; in suspected duodenal ulcer or Zollinger-Ellison
tumor |

|
|
| Pregnancy Risk
Factor |
|
|
C |

|
|
| Adverse
Reactions |
|
|
>10%: Gastrointestinal: Abdominal pain, desire to defecate, nausea,
vomiting
1% to 10%:
Cardiovascular: Flushing, tachycardia, palpitations, hypotension, faintness
Central nervous system: Dizziness, headache
Respiratory: Dyspnea
<1%: Miscellaneous: Allergic reactions |

|
|
| Stability |
|
|
Refrigerate |

|
|
| Mechanism of
Action |
|
|
Excites the oxyntic cells of the stomach to secrete to their maximum capacity
similar to the naturally occurring hormone, gastrin |

|
|
| Pharmacodynamics/Kinetics |
|
|
Absorption: I.M., S.C.: Well absorbed
Serum half-life: 1 minute |

|
|
| Usual Dosage |
|
|
Adults:
I.V. infusion: 0.1-12 mcg/kg/hour in 0.9% sodium chloride
|

|
|
| Dietary
Considerations |
|
|
Patient should fast from food and liquids overnight and be instructed not to
take antacids on the morning of the test nor drugs that inhibit gastric
secretion |

|
|
| Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
|
No information available to require special precautions |

|
|
| Dental Health:
Effects on Dental Treatment |
|
|
No effects or complications reported |

|
|
| Patient
Information |
|
|
Fast from food and liquids overnight and do not take antacids on the morning
of the test nor drugs that inhibit gastric secretion |

|
|
| Nursing
Implications |
|
|
Refrigerate |

|
|
| Dosage Forms |
|
|
Injection: 0.25 mg/mL (2 mL) |

|
|
Copyright © 2007 Drugs Area
|